{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T20:17:59Z","timestamp":1780517879858,"version":"3.54.1"},"reference-count":29,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"5","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Glob Oncol"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>Genomic assays are commonly used to predict breast cancer recurrence but remain inaccessible in low-resource settings, often leading to unnecessary chemotherapy. We previously optimized a LASSO-penalized regression model incorporating quantitative clinicopathologic features to predict genomic risk. Here, we present validation and clinical utility in an international cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>We retrospectively analyzed patients with early-stage hormone receptor\u2013positive\/human epidermal growth factor receptor 2\u2013negative breast cancer treated in Chicago and Rio de Janeiro. Model accuracy for predicting high Oncotype DX (ODX) scores was evaluated using area under the receiver operating characteristic curve (AUROC) in Chicago cohorts. Survival outcomes\u2014disease-free interval (DFI), disease-free survival (DFS), and overall survival (OS)\u2014were compared by Kaplan-Meier and Cox regression using a predefined threshold for high-risk disease. Adjusted models examined chemotherapy benefit by predicted risk. Estimated cost was compared between testing strategies and chemotherapy allocation in Brazil and the United States. The study was approved by the Brazilian Research Ethics Committee on October 24, 2024, under CAAE number 67993323.6.0000.5274. Due to the retrospective nature of the study, which involved only data collection from electronic medical records, the requirement for informed consent was waived by the Ethics Committee. Additionally, the study is covered under Institutional Review Board 22-0707 at the University of Chicago.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      We included 1,566 patients from Chicago and 296 from Rio de Janeiro. The estrogen receptor\/progesterone receptor\/Ki-67 model showed strong performance for ODX prediction (AUROC 0.81 and 0.91).Compared with high-risk patients, low-risk patients had superior 5-year DFI (98.0%\n                      <jats:italic toggle=\"yes\">v<\/jats:italic>\n                      81.6%, hazard ratio [HR], 11.89,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .001), DFS (91.3%\n                      <jats:italic toggle=\"yes\">v<\/jats:italic>\n                      77.5%, HR, 3.41,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .001), and OS (92.1%\n                      <jats:italic toggle=\"yes\">v<\/jats:italic>\n                      87.3%, HR, 2.47,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .02). Chemotherapy provided no significant benefit in the low-risk group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Our model accurately predicted recurrence and outcomes across US and Brazilian cohorts, supporting treatment de-escalation in low-risk patients and promoting equitable care where genomic testing is limited.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/go-25-00705","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T19:59:08Z","timestamp":1780084748000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":0,"title":["Accessible Clinical Tool for Prognosis and Chemotherapy Prediction in Hormone Receptor\u2013Positive\/Human Epidermal Growth Factor Receptor 2\u2013Negative Breast Cancer in Diverse and Low-Resource Settings"],"prefix":"10.1200","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-7607-3142","authenticated-orcid":true,"given":"Rubem Jose","family":"Peres Moreira","sequence":"first","affiliation":[{"name":"Medical Oncology, Instituto Nacional de Cancer, Rio de Janeiro, Brazil"},{"name":"Medical Oncology, Instituto D\u2019Or de Pesquisa e Ensino, Rio de Janeiro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2465-8854","authenticated-orcid":true,"given":"Jose","family":"Bines","sequence":"additional","affiliation":[{"name":"Medical Oncology, Instituto Nacional de Cancer, Rio de Janeiro, Brazil"},{"name":"Medical Oncology, Instituto D\u2019Or de Pesquisa e Ensino, Rio de Janeiro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asim","family":"Dhungana","sequence":"additional","affiliation":[{"name":"Pritzker School of Medicine, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1119-2146","authenticated-orcid":true,"given":"Jincong Q.","family":"Freeman","sequence":"additional","affiliation":[{"name":"Department of Public Health Sciences, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6609-7188","authenticated-orcid":true,"given":"Poornima","family":"Saha","sequence":"additional","affiliation":[{"name":"Department of Medicine, NorthShore University HealthSystem, Evanston, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0687-6841","authenticated-orcid":true,"given":"Megan E.","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Department of Pathology, NorthShore University HealthSystem, Evanston, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Surgery, NorthShore University HealthSystem, Evanston, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elbio M.","family":"Flores","sequence":"additional","affiliation":[{"name":"Department of Pathology, Ingalls Memorial Hospital, Harvey, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4041-1678","authenticated-orcid":true,"given":"Dezheng","family":"Huo","sequence":"additional","affiliation":[{"name":"Department of Public Health Sciences, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2801-7456","authenticated-orcid":true,"given":"Alexander T.","family":"Pearson","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0598-9295","authenticated-orcid":true,"given":"Isabele Avila","family":"Small","sequence":"additional","affiliation":[{"name":"Data Management and Analysis, Instituto Nacional de Cancer, Rio de Janeiro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9936-1599","authenticated-orcid":true,"given":"Olufunmilayo I.","family":"Olopade","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6039-1141","authenticated-orcid":true,"given":"Frederick Matthew","family":"Howard","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_8_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03502-3"},{"key":"e_1_3_8_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.3845"},{"key":"e_1_3_8_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2019.01.008"},{"key":"e_1_3_8_5_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.927748"},{"key":"e_1_3_8_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03007"},{"key":"e_1_3_8_7_2","volume-title":"Breast Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology","author":"Gradishar WJ","unstructured":"Gradishar WJ, Moran MS, Abraham J, et al: Breast Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology. https:\/\/www.nccn.org"},{"key":"e_1_3_8_8_2","unstructured":"Cobertura Assistencial\u2014Percentual de benefici\u00e1rios de planos privados de sa\u00fade\u20142023. https:\/\/www.gov.br\/ans"},{"key":"e_1_3_8_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.2489"},{"key":"e_1_3_8_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-017-4170-3"},{"key":"e_1_3_8_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2019.05.006"},{"key":"e_1_3_8_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2019.07.006"},{"key":"e_1_3_8_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-024-00651-5"},{"key":"e_1_3_8_14_2","doi-asserted-by":"publisher","DOI":"10.2307\/2531595"},{"key":"e_1_3_8_15_2","doi-asserted-by":"publisher","DOI":"10.1177\/17588359221141760"},{"key":"e_1_3_8_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21464"},{"key":"e_1_3_8_17_2","doi-asserted-by":"publisher","DOI":"10.1590\/S0080-623420140000400018"},{"key":"e_1_3_8_18_2","first-page":"658","article-title":"Prediction of the Oncotype DX recurrence score: Use of pathology-generated equations derived by linear regression analysis","volume":"26","author":"Klein ME","year":"2013","unstructured":"Klein ME, Dabbs DJ, Shuai Y, et al: Prediction of the Oncotype DX recurrence score: Use of pathology-generated equations derived by linear regression analysis. Mod 26:658-664, 2013","journal-title":"Mod"},{"key":"e_1_3_8_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12282-018-0860-x"},{"key":"e_1_3_8_20_2","doi-asserted-by":"publisher","DOI":"10.4048\/jbc.2018.21.2.222"},{"key":"e_1_3_8_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2018.09.011"},{"key":"e_1_3_8_22_2","doi-asserted-by":"crossref","unstructured":"P258: Factors associated with distant recurrence (DR) risk in patients (pts) with HR+\/HER\u2212 early breast cancer (EBC): A machine learning (ML) model-based analysis using real-world (RW) data. 19th St. Gallen International Breast Cancer Conference\/The Breast 80S S1-S188 2025","DOI":"10.1016\/j.breast.2025.104097"},{"key":"e_1_3_8_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00727-2"},{"key":"e_1_3_8_24_2","doi-asserted-by":"publisher","DOI":"10.1101\/2025.07.21.25331907"},{"key":"e_1_3_8_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-023-00530-5"},{"key":"e_1_3_8_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.549"},{"key":"e_1_3_8_27_2","article-title":"Multi-modal AI for comprehensive breast cancer prognostication","author":"Witowski J","year":"2025","unstructured":"Witowski J, Zeng KG, Cappadona J, et al: Multi-modal AI for comprehensive breast cancer prognostication. arXiv. 2025. arXiv:2410.21256","journal-title":"arXiv"},{"key":"e_1_3_8_28_2","volume-title":"PORTARIA CONJUNTA SAES\/SECTICS N\u00ba 17, DE 25 DE NOVEMBRO DE 2024","author":"MINIST\u00c9RIO DA SA\u00daDE; SECRETARIA DE ATEN\u00c7\u00c3O ESPECIALIZADA \u00c0 SA\u00daDE; SECRETARIA DE CI\u00caNCIA, TECNOLOGIA, INOVA\u00c7\u00c3O E DO COMPLEXO ECON\u00d4MICO-INDUSTRIAL DA SA\u00daDE","year":"2022","unstructured":"MINIST\u00c9RIO DA SA\u00daDE; SECRETARIA DE ATEN\u00c7\u00c3O ESPECIALIZADA \u00c0 SA\u00daDE; SECRETARIA DE CI\u00caNCIA, TECNOLOGIA, INOVA\u00c7\u00c3O E DO COMPLEXO ECON\u00d4MICO-INDUSTRIAL DA SA\u00daDE: PORTARIA CONJUNTA SAES\/SECTICS N\u00ba 17, DE 25 DE NOVEMBRO DE 2024. 2022. https:\/\/www.gov.br\/conitec\/pt-br\/midias\/protocolos\/pcdt-cancer-de-mama"},{"key":"e_1_3_8_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djt306"},{"key":"e_1_3_8_30_2","volume-title":"Prediction of High-Risk Oncotype-DX Recurrence Score","unstructured":"Prediction of High-Risk Oncotype-DX Recurrence Score. rsncdb.cri.uchicago.edu"}],"container-title":["JCO Global Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/GO-25-00705","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T19:59:20Z","timestamp":1780516760000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/GO-25-00705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1200\/GO-25-00705"],"URL":"https:\/\/doi.org\/10.1200\/go-25-00705","relation":{},"ISSN":["2687-8941"],"issn-type":[{"value":"2687-8941","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"2025-11-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-23","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2500705"}}